BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05722522 (Secukinumab in Rotator Cuff Tendinopathy): BVCT ex-ante prediction vs. reported outcome

On 1 Jul 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 31 Jan 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically probably insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05722522
Drug Name
Secukinumab
Drug MoA
anti-IL17A inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Rotator Cuff Tendinopathy
Human Patients
33
Sponsor
Novartis
Phase
Phase 3

Prediction of , index 1636

Prospective Prediction
Prediction Index
1636
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit in WORC-PSD as an adjunctive therapy to SoC)
Technical Prediction
FAILURE (statistically insignificant additive clinical benefit in WORC-PSD as an adjunctive therapy to SoC)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
214 days in advance
Readout Data Interpretation
secukinumab hasn't met the efficacy threshold and further development discontinued without disclosure of data
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically probably insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Parallel-group, 24 Week, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Active Rotator Cuff Tendinopathy
Phase
Phase 3
Status
Terminated
Enrollment
33
Lead sponsor
Novartis Pharmaceuticals
Conditions
Rotator Cuff Tendinopathy
Interventions
DRUG: Secukinumab; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-08-10
Primary completion
2024-10-17
Completion
2024-12-13
Results first posted
2025-12-02
Primary outcomes
  • Change From Baseline in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) Score at Week 16 (At Week 16)

NCT05722522 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials